FGF21 mRNA Expression Summary
Shown are the FGF21 mRNA ratio values obtained by Agilent microarray analysis in the strains and tissues indicated. A ratio greater than 1 signifies up-regulation in the treatment/condition compared to the reference sample (and vice versa). P values were calculated as described under Materials and Methods. Normalized intensity values are shown for both the treatment/condition and reference samples. The probe sequence used for FGF21 in the Agilent microarray was CCTGAATCTAGGGCTGTTTCTTTTT-GGGTTTCCACTTATTTATTACGGGTATTTATCTTA.
Treatment/Condition: Strain and Tissue | Days | n | Reference: Strain and Tissue | Ratio | P | Intensity Treatment | Intensity Reference |
|---|---|---|---|---|---|---|---|
| Adipose | |||||||
| db/db EWAT + rosiglitazone, 30 mg/kg | 8 | 3 | db/db EWAT + vehicle | 2.2 | <0.01 | 0.42 | 0.19 |
| db/db EWAT + COOH, 30 mg/kg | 8 | 3 | db/db EWAT + vehicle | 2.8 | <0.01 | 0.59 | 0.20 |
| db/db EWAT + vehicle | 8 | 3 | db/db EWAT + vehicle | 0.9 | 0.01 | 0.17 | 0.20 |
| db/db EWAT + vehicle | 8 | 3 | db/+ EWAT + vehicle | 1.1 | 0.03 | 0.14 | 0.12 |
| db/+ EWAT + vehicle | 8 | 3 | db/+ EWAT + vehicle | 1.0 | 0.68 | 0.13 | 0.13 |
| C57BL/6 EWAT + rosiglitazone, 100 mg/kg | 7 | 3 | C57BL/6 EWAT + vehicle | 2.7 | <0.01 | 0.46 | 0.16 |
| C57BL/6 EWAT + WY14643, 30 mg/kg | 7 | 3 | C57BL/6 EWAT + vehicle | 1.7 | <0.01 | 0.31 | 0.17 |
| C57BL/6 EWAT + vehicle | 7 | 3 | C57BL/6 EWAT + vehicle | 1.1 | 0.50 | 0.18 | 0.15 |
| CD1 EWAT + rosiglitazone, 100 mg/kg | 14 | 3 | CD1 EWAT + vehicle, 14 days | 2.7 | <0.01 | 1.26 | 0.42 |
| CD1 EWAT + vehicle | 14 | 3 | CD1 EWAT + vehicle, 14 days | 1.1 | 0.43 | 0.40 | 0.35 |
| CD1 IWAT + rosiglitazone, 100 mg/kg | 14 | 3 | CD1 IWAT + vehicle, 14 days | 2.5 | <0.01 | 0.15 | 0.40 |
| CD1 IWAT + fenofibrate 300 mg/kg | 14 | 3 | CD1 IWAT + vehicle, 14 days | 1.1 | 0.61 | 0.12 | 0.14 |
| CD1 IWAT + vehicle | 14 | 3 | CD1 IWAT + vehicle, 14 days | 1.0 | 0.85 | 0.18 | 0.18 |
| 3T3-L1 Adipocytes + rosiglitazone, 10 μM | 2 | 3T3-L1 Adipocytes + vehicle | 6.6 | <0.01 | 0.44 | 0.07 | |
| 3T3-L1 Adipocytes + COOH, 10 μM | 2 | 3T3-L1 Adipocytes + vehicle | 8.6 | <0.01 | 0.54 | 0.06 | |
| 3T3-L1 Adipocytes + WY14643, 10 μM | 2 | 3T3-L1 Adipocytes + vehicle | 1.0 | 0.89 | 0.06 | 0.06 | |
| 3T3-L1 Adipocytes + vehicle | 3 | 3T3-L1 Adipocytes + vehicle | 1.0 | 0.58 | 0.06 | 0.05 | |
| C57BL/6 EWAT + fast | 1 | 4 | C57BL/6 EWAT + chow | 2.1 | <0.01 | 0.65 | 0.29 |
| C57BL/6 EWAT + HFD | 70 | 4 | C57BL/6 EWAT + chow | 1.8 | <0.01 | 0.62 | 0.32 |
| C57BL/6 EWAT + chow | 4 | C57BL/6 EWAT + chow | 1.0 | 0.71 | 0.27 | 0.26 | |
| Liver | |||||||
| 129Sv Liver + fenofibrate, 200 mg/kg | 7 | 3 | 129Sv Liver + vehicle | 3.8 | <0.01 | 2.52 | 0.66 |
| 129Sv Liver + rosiglitazone, 100 mg/kg | 7 | 3 | 129Sv Liver + vehicle | 0.8 | 0.12 | 0.48 | 0.59 |
| 129Sv Liver + vehicle | 7 | 3 | 129Sv Liver + vehicle | 1.0 | 0.96 | 0.62 | 0.59 |
| 129Sv PPARαKO Liver + fenofibrate, 200 mg/kg | 7 | 3 | 129Sv PPARαKO Liver + vehicle | 1.0 | 0.78 | 0.12 | 0.13 |
| 129Sv PPARαKO Liver + rosiglitazone, 100 mg/kg | 7 | 3 | 129Sv PPARαKO Liver + vehicle | 1.2 | 0.22 | 0.11 | 0.10 |
| 129Sv PPARαKO Liver + vehicle | 7 | 3 | 129Sv Liver + vehicle | 0.2 | <0.01 | 0.17 | 0.77 |
| C57BL/6 Liver + rosiglitazone, 100 mg/kg | 7 | 3 | C57BL/6 Liver + vehicle | 1.2 | 0.32 | 0.30 | 0.25 |
| C57BL/6 Liver + WY14643, 30 mg/kg | 7 | 3 | C57BL/6 Liver + vehicle | 4.1 | <0.01 | 1.27 | 0.26 |
| C57BL/6 Liver + vehicle | 7 | 3 | C57BL/6 Liver + vehicle | 1.0 | 0.82 | 0.27 | 0.29 |
| db/db Liver + rosiglitazone, 30 mg/kg | 8 | 3 | db/db Liver + vehicle | 1.2 | 0.26 | 0.24 | 0.20 |
| db/db Liver + vehicle | 8 | 3 | db/db Liver + vehicle | 0.8 | 0.29 | 0.21 | 0.23 |
| db/db Liver + vehicle | 8 | 5 | db/+ Liver + vehicle | 0.9 | 0.39 | 0.54 | 0.58 |
| C57BL/6 Liver + fast | 1 | 4 | C57BL/6 Liver + chow | 8.1 | <0.01 | 4.66 | 0.45 |
| C57BL/6 Liver + HFD | 70 | 4 | C57BL/6 Liver + chow | 8.7 | <0.01 | 3.05 | 0.34 |
| C57BL/6 Liver + chow |
| 4 | C57BL/6 Liver + chow | 0.9 | 0.67 | 0.32 | 0.34 |
HFD, high-fat diet.